Cross Country Healthcare, Inc.

NasdaqGS:CCRN Stock Report

Mkt Cap: US$841.3m

We’ve recently updated our valuation analysis.

Cross Country Healthcare Valuation

Is CCRN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CCRN?

Other financial metrics that can be useful for relative valuation.

CCRN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.4x
Enterprise Value/EBITDA3.4x
PEG Ratio-0.3x

Price to Earnings Ratio vs Peers

How does CCRN's PE Ratio compare to its peers?

The above table shows the PE ratio for CCRN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average19.1x
FLGT Fulgent Genetics
6.2x-67.3%US$890.0m
DCGO DocGo
25.9x11.0%US$894.9m
NRC National Research
33.6xn/aUS$1.1b
EHAB Enhabit
10.6x-13.4%US$661.9m
CCRN Cross Country Healthcare
4.5x-16.8%US$841.3m


Price to Earnings Ratio vs Industry

How does CCRN's PE Ratio compare vs other companies in the US Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.4%
n/an/an/a
No more companies


Price to Earnings Ratio vs Fair Ratio

What is CCRN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CCRN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4.5x
Fair PE Ratio14.3x

Price-To-Earnings vs Fair Ratio: CCRN is good value based on its Price-To-Earnings Ratio (4.5x) compared to the estimated Fair Price-To-Earnings Ratio (14.3x).


Share Price vs Fair Value

What is the Fair Price of CCRN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CCRN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$22.85
US$36.79
+61.0%
15.1%US$45.00US$30.00n/a7
Mar ’24US$26.65
US$37.92
+42.3%
13.7%US$45.00US$30.50n/a6
Feb ’24US$28.98
US$39.33
+35.7%
15.4%US$45.00US$31.00n/a6
Jan ’24US$26.57
US$39.33
+48.0%
15.4%US$45.00US$31.00n/a6
Dec ’23US$35.35
US$39.33
+11.3%
15.4%US$45.00US$31.00n/a6
Nov ’23US$37.71
US$36.17
-4.1%
20.3%US$45.00US$26.00n/a6
Oct ’23US$28.37
US$36.17
+27.5%
20.3%US$45.00US$26.00n/a6
Sep ’23US$24.64
US$34.33
+39.3%
21.7%US$44.00US$23.00n/a6
Aug ’23US$26.57
US$34.67
+30.5%
24.8%US$44.00US$21.00n/a6
Jul ’23US$21.29
US$34.33
+61.3%
26.6%US$44.00US$19.00n/a6
Jun ’23US$17.36
US$35.50
+104.5%
26.1%US$44.00US$19.00n/a6
May ’23US$18.74
US$36.83
+96.5%
19.4%US$44.00US$27.00n/a6
Apr ’23US$22.52
US$35.00
+55.4%
18.4%US$44.00US$27.00n/a6
Mar ’23US$21.39
US$35.00
+63.6%
18.4%US$44.00US$27.00US$26.656
Feb ’23US$21.98
US$29.67
+35.0%
8.6%US$33.00US$27.00US$28.986
Jan ’23US$27.76
US$25.83
-6.9%
20.2%US$33.00US$18.00US$26.576
Dec ’22US$25.46
US$25.57
+0.4%
21.2%US$33.00US$18.00US$35.357
Nov ’22US$21.37
US$21.00
-1.7%
10.2%US$24.00US$18.00US$37.717
Oct ’22US$21.27
US$20.71
-2.6%
10.2%US$24.00US$18.00US$28.377
Sep ’22US$21.00
US$20.57
-2.0%
11.0%US$24.00US$18.00US$24.647
Aug ’22US$16.42
US$16.58
+1.0%
11.6%US$20.00US$13.50US$26.576
Jul ’22US$16.47
US$16.25
-1.3%
13.3%US$20.00US$13.50US$21.296
Jun ’22US$16.51
US$15.42
-6.6%
12.8%US$17.00US$12.00US$17.366
May ’22US$13.32
US$12.86
-3.5%
14.1%US$15.00US$10.00US$18.747
Apr ’22US$12.31
US$12.71
+3.3%
13.1%US$15.00US$10.00US$22.527
Mar ’22US$11.86
US$11.46
-3.3%
15.5%US$14.00US$8.25US$21.397


Discover undervalued companies